Emerging therapies for hemophilia: A new era of care and the role of the interdisciplinary team

Michelle Witkop, Susan Cutter, Joann Deutsche, Maria Santaella, Robin Chapman, Jennifer Lafranco, Angela Lambing

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


The introduction of new hemophilia management therapies, targeting extended half-lives through bioengineering, ushers in an era of potential promise and increasing complexity, more so for those with hemophilia B than hemophilia A. Questions arise for patients, caregivers, and hemophilia treatment center (HTC) staff about how to assess and incorporate novel therapies and how to determine whether new therapies offer a distinct advantage over established treatment routines. Nurses and other interdisciplinary HTC staff are well positioned to assess, educate, and support patients and families in navigating this rapidly changing landscape. To support these challenging efforts, this review offers a perspective on issues affecting therapeutic transitions and provides tools to foster ongoing adherence.

Original languageEnglish (US)
Pages (from-to)790-802
Number of pages13
JournalSeminars in thrombosis and hemostasis
Issue number7
StatePublished - Oct 1 2014


  • adherence
  • cultural
  • hemophilia
  • psychosocial
  • therapy transition

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Emerging therapies for hemophilia: A new era of care and the role of the interdisciplinary team'. Together they form a unique fingerprint.

Cite this